ARM and CARM Announce Strategic Partnership to Advance Regulatory Harmonization for Cell and Gene Therapies in the US and Korea

San Diego, CA – June 4, 2024

Pictured: Leadership from ARM and CARM at the signing ceremony.

The Alliance for Regenerative Medicine (ARM) and the Council for Advanced Regenerative Medicine (CARM) in Korea signed a Memorandum of Understanding (MOU) to expand overseas exchange and harmonize regulations for cell and gene therapies (CGTs).

This landmark partnership seeks to bolster efforts in aligning regulatory frameworks between the United States and Korea and jointly monitoring and reporting on trends within the field. It renews and reinvigorates a previous partnership between the two organizations that had been on pause during and immediately after the COVID-19 pandemic.

The agreement will include:

  • Reporting on trends in the organizations’ respective regions;
  • Providing partnership support for each member company;
  • Participating in international forums for regulatory harmonization;
  • Collaborating on standardization of the regenerative medicine industry through national standardization organizations;
  • Exchanging information on CGT industry status surveys in both countries and exploring the possibility of collaborating on joint publications.

The signing ceremony occurred in San Diego, California, at the BIO International Convention. CEO Timothy Hunt and Vice President Laura Stringham attended the ceremony representing ARM. From CARM, Chairman Duckjoo Lee, Honorary Chairman BG Rhee (Chairman of GI-Innovation), Kyung-Sun Kang (Founder of Kangstem Biotech), James Park (CEO of GC Cell), and Young Kim (CEO of Synex) attended, all of whom serve on the board of directors of CARM. In addition to the signing ceremony, CARM executives attended ARM’s Cell & Gene Reception on June 3, where they had the opportunity to network with ARM executives and key stakeholders.

“As we embark on this renewed collaboration with CARM, we are proud to reaffirm our commitment to driving innovation and expanding patient access to transformative therapies,” said ARM Chief Executive Officer Tim Hunt. “By aligning our efforts and sharing expertise, we can accelerate the global development of life-saving treatments.”

Dr. Duckjoo Lee, Chairman of CARM, has expressed profound enthusiasm for the reinvigorated collaboration between CARM and ARM. Dr. Lee remarked, “We are thrilled to once again solidify the partnership between CARM and ARM. This collaboration heralds a new era of innovation and growth in the field of advanced regenerative medicine.”

About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and modernize healthcare systems so patients benefit from durable, potentially curative treatments.

As the global voice of the sector, we represent more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.

About the Council for Advanced Regenerative Medicine
CARM is an industry association established on May 9, 2016. It aims to vitalize domestic industry and facilitate international collaboration in advanced regenerative medicine. CARM endeavors to facilitate regulatory harmonization, foster international cooperation, and cultivate business-to-business partnerships within the realm of advanced regenerative medicine. Through the voluntary engagement of companies in subcommittees administered by CARM, it directly contributes to the establishment of an industrial ecosystem.

As a premier representative organization in advanced regenerative medicine in Korea, CARM boasts a membership of 92 full members, 23 associate members, and 115 member companies.